Compare Twist Bioscience Corp (TWST) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Zillow Group Inc Class A — how do they compare? Twist Bioscience Corp trades at $160.15 (market cap $10.08B), while Zillow Group Inc Class A trades at $29.8 (market cap $6.59B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Zillow Group Inc Class A for 86 Days on average.
| TWST | ZG | |
|---|---|---|
Market Cap | $10.08B | $6.59B |
Volume | 4,229,037 | 1,361,381 |
Sector | Health | Media |
52-Week High | $205.00 | $74.58 |
52-Week Low | $25.45 | $27.70 |
Typical Hold Time | 27 Days | 86 Days |
Enterprise Value | $10.01B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Zillow Group (ZG) trades at $29.53, up 5.58% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. Fundamentally, the company reported a return to profitability in 2025 with net income of $23 million, and revenue is projected to grow to $2.8 billion in 2026. Recent news highlights the company's focus on AI integration and a challenging housing market environment.
The outlook is cautiously optimistic, with a consensus price target of $48.87 suggesting significant upside. Key opportunities include revenue growth and market share gains, while risks involve housing market volatility and intense competition. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
